EDURANT
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $453,072 | 7 | 0 |
| 2023 | $711,073 | 4 | 1 |
| 2022 | $2.3M | 10 | 0 |
| 2021 | $113.80 | 4 | 3 |
| 2020 | $17,676 | 16 | 16 |
| 2019 | $137,865 | 144 | 25 |
| 2018 | $357,278 | 140 | 23 |
| 2017 | $101,405 | 16 | 9 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.9M | 32 | 96.8% |
| Consulting Fee | $102,000 | 36 | 2.5% |
| Travel and Lodging | $21,747 | 95 | 0.5% |
| Food and Beverage | $5,473 | 178 | 0.1% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1, Single-blind, Randomized, Parallel-group Study in Healthy Participants to Investigate the Single-dose Pharmacokinetics, Safety and Tolerability of Rilpivirine After Subcutaneous Administration of a Rilpivirine Extended-Release Suspension | Janssen Research & Development, LLC | $3.4M | 0 |
| A Phase 1, Open-label, Randomized, Parallel-group Study in Healthy Subjects to Investigate the Effect of Different Particle Sizes on the Single-dose Pharmacokinetics of Rilpivirine After Intramuscular Injection of a Long-acting Nanosuspension | Janssen Research & Development, LLC | $305,726 | 0 |
| A Phase IV 96 Week, Open Label, Pilot Study of PREZISTA Boosted by Cobicistat in Combination with EDURANT to Treat HIV+ Naive Subjects (PREZENT) | Janssen Research & Development, LLC | $179,412 | 0 |
Top Doctors Receiving Payments for EDURANT — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , PA-C | Physician Assistant | Brooklyn, NY | $37.17 | 1 |
| , MD | Internal Medicine | San Francisco, CA | $35.52 | 2 |
| , MD | Internal Medicine | Woonsocket, RI | $30.47 | 1 |
| , MD | Specialist | Bronx, NY | $26.10 | 2 |
| , MD | Internal Medicine | Brooklyn, NY | $23.71 | 1 |
| Joseph Guadalupe | Internal Medicine | Bronx, NY | $23.71 | 1 |
| , M.D | Infectious Disease | Brooklyn, NY | $23.71 | 1 |
| , MD | Specialist | Flushing, NY | $23.71 | 1 |
| , M.D | Pulmonary Disease | Brooklyn, NY | $23.71 | 1 |
| , MD | Internal Medicine | Elmhurst, NY | $23.71 | 1 |
| , M.D | Hospitalist | Brooklyn, NY | $23.71 | 1 |
| , M.D | Internal Medicine | Brooklyn, NY | $23.71 | 1 |
| , MD | Infectious Disease | Cleveland, OH | $21.16 | 1 |
| , D.O | Infectious Disease | Akron, OH | $21.16 | 1 |
| , MD | Infectious Disease | Akron, OH | $21.16 | 1 |
| , MD | Infectious Disease | Cleveland, OH | $21.16 | 1 |
| , M.D | Internal Medicine | Akron, OH | $21.16 | 1 |
| , MD | Infectious Disease | Akron, OH | $21.16 | 1 |
| , M.D | Clinic/Center | Akron, OH | $21.16 | 1 |
| , MD | Internal Medicine | Royal Oak, MI | $21.16 | 1 |
| , DO | Adult Medicine | Philadelphia, PA | $19.03 | 1 |
| , OD | Ophthalmology | Los Angeles, CA | $19.03 | 1 |
| , MD | Infectious Disease | Daytona Beach, FL | $17.43 | 1 |
| , MD | Internal Medicine | Daytona Beach, FL | $17.43 | 1 |
| , MD | Internal Medicine | Stamford, CT | $13.07 | 1 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $4.0M
- Total Doctors 55
- Transactions 341
About EDURANT
EDURANT is a drug associated with $4.0M in payments to 55 healthcare providers, recorded across 341 transactions in the CMS Open Payments database. The primary manufacturer is Janssen Research & Development, LLC.
Payment data is available from 2017 to 2024. In 2024, $453,072 was paid across 7 transactions to 0 doctors.
The most common payment nature for EDURANT is "Unspecified" ($3.9M, 96.8% of total).
EDURANT is associated with 3 research studies, including "A Phase 1, Single-blind, Randomized, Parallel-group Study in Healthy Participants to Investigate the Single-dose Pharmacokinetics, Safety and Tolerability of Rilpivirine After Subcutaneous Administration of a Rilpivirine Extended-Release Suspension" ($3.4M).